Literature DB >> 10652599

Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine.

E Sugikawa1, T Hosoi, N Yazaki, M Gamanuma, N Nakanishi, M Ohashi.   

Abstract

Wild-type p53 causes cell-cycle arrest at late G1 phase and induction of apoptosis by up- regulation of waf1 and bax, respectively. Although in many cancer cells p53 is frequently mutated and loses its functions, we have proposed that mutant p53 may be involved in the anticancer mechanism of 9-hydroxy ellipticine (9HE). It was shown using flow cytometry that 9HE (10 microM) caused induction of apoptosis in G1 phase of the cell cycle in mutant p53 (p53ala143, p53his175, orp53his273) transfected Saos-2 cells, but not in p53-deficient parental Saos-2 cells. Similar induction of apoptosis was observed 24-48 h after treatment with 9HE in mutant p53-containing SW480, SK-BR-3 and MKN-1, but not in p53-deficient KATO m cells. Using G1 phase cells isolated by centrifugal elutriation, it was confirmed that 9HE caused cell cycle arrest at G1 phase and subsequently induced G1 phase-restricted apoptosis. In accordance with the induction of arrest and apoptosis in G1 phase, 9HE caused up-regulation of waf1 and bax mRNA in mutant p53-containing cells, but not in p53-deficient parental Saos-2 cells. In control experiments, adriamycin (ADR) showed neither G1-restricted apoptosis nor elevation of bax mRNA. It is suggested that 9HE may cause G1 arrest and induction of G1 phase-restricted apoptosis by restoring the wild-type function of mutant p53 protein.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10652599

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  16 in total

1.  Replication of damaged DNA in vitro is blocked by p53.

Authors:  Jianmin Zhou; Carol Prives
Journal:  Nucleic Acids Res       Date:  2003-07-15       Impact factor: 16.971

Review 2.  Targeting the p53 pathway.

Authors:  Vita M Golubovskaya; William G Cance
Journal:  Surg Oncol Clin N Am       Date:  2013-07-30       Impact factor: 3.495

3.  Old drug, new target: ellipticines selectively inhibit RNA polymerase I transcription.

Authors:  William J Andrews; Tatiana Panova; Christophe Normand; Olivier Gadal; Irina G Tikhonova; Konstantin I Panov
Journal:  J Biol Chem       Date:  2013-01-04       Impact factor: 5.157

4.  Effect of new olivacine derivatives on p53 protein level.

Authors:  Tomasz Gębarowski; Benita Wiatrak; Katarzyna Gębczak; Beata Tylińska; Kazimierz Gąsiorowski
Journal:  Pharmacol Rep       Date:  2020-01-08       Impact factor: 3.024

Review 5.  Translational approaches targeting the p53 pathway for anti-cancer therapy.

Authors:  Frank Essmann; Klaus Schulze-Osthoff
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

Review 6.  Mutant p53: one name, many proteins.

Authors:  William A Freed-Pastor; Carol Prives
Journal:  Genes Dev       Date:  2012-06-15       Impact factor: 11.361

7.  p53 Activates Either Survival or Apoptotic Signaling Responses in Lupulone-Treated Human Colon Adenocarcinoma Cells and Derived Metastatic Cells.

Authors:  Virginie Lamy; Souad Bousserouel; Francine Gossé; Carole Minker; Annelise Lobstein; Francis Raul
Journal:  Transl Oncol       Date:  2010-10-01       Impact factor: 4.243

Review 8.  Restoring p53 tumor suppressor activity as an anticancer therapeutic strategy.

Authors:  Jesse D Martinez
Journal:  Future Oncol       Date:  2010-12       Impact factor: 3.404

9.  Mutant p53 exhibits trivial effects on mitochondrial functions which can be reactivated by ellipticine in lymphoma cells.

Authors:  Fei Wang; Jianfeng Liu; Delira Robbins; Kerri Morris; Amos Sit; Yong-Yu Liu; Yunfeng Zhao
Journal:  Apoptosis       Date:  2011-03       Impact factor: 4.677

10.  Ellipticine derivative induces potent cytostatic effect in acute myeloid leukaemia cells.

Authors:  E G Russell; E C O'Sullivan; C M Miller; J Stanicka; F O McCarthy; T G Cotter
Journal:  Invest New Drugs       Date:  2014-08-10       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.